MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why ADRX Stock slipped -0.56% Today — RQD Quant Desk Flash
$17.85 -0.56% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $17.80
ADARx Pharmaceuticals Inc. (ADRX) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $1.91B
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $17.80 (-0.29%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 1.3% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY • 50.1% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-2.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ADRX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (52/100 Composite)
🔍 WHY ADRX SCORES 52/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (25% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (23% of score)
SEC XBRL Trailing 12 Months: 1.3% FCF Margin ($53.4M FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$17.78-0.7% Next Q
44
Q2 (-2Q)Grade D$17.65-0.1% Next Q
47
Q3 (-1Q)Grade D$17.63+1.2% Next Q
49
CurrentGrade D+$17.85-1.1% Hist 90D α
52
Trajectory: D (44) → D+ (52)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ADRX Turnaround Squeeze
While ADRX currently carries a cautious 52/100 (D+) rating due to Whale & Options Positioning (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($18.21) and Max Pain ($18.74) forces dealer call-delta covering toward $24.37.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ADRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ADRX Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ADRX Stock slipped -0.56% Today — RQD Quant Desk Flash
ADARx Pharmaceuticals Inc. (ADRX) slipped -0.56% to $17.85, trading at 22% of its 52-week range ($16.3 – $23.21). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 22% of its 52-week range ($16.3 – $23.21) with RSI-14 at 36.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $17.85 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 52% gross margin and $53.4M annual free cash flow.
Live ADRX Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ADRX)
- ✓Walkthrough of ADRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ADRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -7.75%📐 HORIZONTAL RANGE
2026-10-30O $18.10H $18.10L $16.30C $17.85VOL 542.3K
RES: $19.18SUP: $16.58SMA50: $18.21
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ADRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ADRX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ADRX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ADRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ADRX)
Health Care Rank #315 of 1016
⚔️ BRVE vs ADRX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ADRX vs. BRVE, TRAX, MLYS, ZBIO)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, ADARx Pharmaceuticals Inc. (ADRX) ranks #315 by composite RQD confidence (52/100, grade D+) and #272 by equity capitalization ($1.91B). Within this direct 5-issuer industry benchmark cohort, ADRX leads on earnings valuation at N/A trailing P/E, while MLYS leads on capital efficiency and profitability with -28.4% ROIC and — gross margin. ADRX currently leads its immediate peer cohort in composite quantitative strength at 52/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ADRX
ACTIVE
ADARx Pharmaceuticals Inc. | D+ | 52/100 | — | — | — | -0.56% | $1.91B | Benchmark Subject |
| BRVE Braveheart Bio Inc. | D | 47/100 | — | — | — | -2.62% | $1.91B | /brve-vs-adrx → |
| TRAX First Tracks Biotherapeutics Inc. | E | 33/100 | — | — | -35.0% | -1.08% | $1.90B | /trax-vs-adrx → |
| MLYS Mineralys Therapeutics Inc. | D- | 43/100 | — | — | -28.4% | -0.65% | $1.88B | /mlys-vs-adrx → |
| ZBIO Zenas BioPharma Inc. | D- | 39/100 | — | — | -35.0% | -0.04% | $1.87B | /zbio-vs-adrx → |
2. ADRX Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTADARx Pharmaceuticals Inc. (ADRX) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $1.91B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. ADRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ADRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, ADARx Pharmaceuticals Inc. (NASDAQ: ADRX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $17.85 (-0.56% 1D, market cap $1.91B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, ADRX ranks #315 in composite RQD confidence.
How does ADRX compare to BRVE and TRAX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ADRX carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, BRVE (Braveheart Bio Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $1.91B) and TRAX (First Tracks Biotherapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $1.90B). Among the 5-stock peer group, ADRX leads on earnings multiple (N/A) while MLYS leads on capital efficiency (-28.4% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ADRX?
For ADARx Pharmaceuticals Inc. (ADRX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #315 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ADRX trading relative to its 50-day, 200-day, and 52-week technical levels?
ADRX last traded at $17.85 (-0.56% on volume of 402,026 shares), positioning the stock -1.98% below its 50-day simple moving average ($18.21) and -1.71% below its 200-day simple moving average ($18.16). Across its 52-week range of $16.30 to $23.21, ADRX sits at the 22.4% percentile with a 14-day RSI of 36.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($15.62 to $20.08).
ADRX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ADRX stock moving today?
Why ADRX Stock slipped -0.56% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.